EMFAT
RETA

Emerald Mutual Fund Advisers Trust’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Quarter Market Value Status Shares Shares
Change %
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-255,387
Closed -$26M 259
2023
Q2
$26M Buy
255,387
+369
+0.1% +$37.6K 1.41% 12
2023
Q1
$23.2M Sell
255,018
-271,427
-52% -$24.7M 1.37% 14
2022
Q4
$20M Buy
526,445
+85,727
+19% +$3.26M 1.24% 26
2022
Q3
$11.1M Buy
440,718
+189,450
+75% +$4.76M 0.7% 60
2022
Q2
$7.64M Buy
251,268
+33,262
+15% +$1.01M 0.44% 88
2022
Q1
$7.14M Buy
218,006
+43,690
+25% +$1.43M 0.32% 103
2021
Q4
$4.6M Sell
174,316
-106,500
-38% -$2.81M 0.16% 131
2021
Q3
$28.3M Buy
280,816
+28,340
+11% +$2.85M 0.98% 40
2021
Q2
$35.7M Buy
252,476
+979
+0.4% +$139K 1.17% 22
2021
Q1
$25.1M Buy
+251,497
New +$25.1M 0.83% 45
2020
Q3
Sell
-57,635
Closed -$8.99M 369
2020
Q2
$8.99M Sell
57,635
-41,739
-42% -$6.51M 0.42% 82
2020
Q1
$14.3M Buy
99,374
+1,570
+2% +$227K 0.9% 35
2019
Q4
$20M Sell
97,804
-169,517
-63% -$34.7M 0.82% 42
2019
Q3
$21.5M Sell
267,321
-92,649
-26% -$7.44M 0.95% 30
2019
Q2
$34M Hold
359,970
1.35% 16
2019
Q1
$30.8M Sell
359,970
-126,240
-26% -$10.8M 1.23% 20
2018
Q4
$27.3M Buy
486,210
+41,718
+9% +$2.34M 1.27% 11
2018
Q3
$36.3M Sell
444,492
-42,249
-9% -$3.45M 1.23% 9
2018
Q2
$17M Buy
486,741
+15,627
+3% +$546K 0.62% 57
2018
Q1
$9.66M Buy
471,114
+11,930
+3% +$245K 0.38% 104
2017
Q4
$13M Sell
459,184
-13,867
-3% -$393K 0.52% 66
2017
Q3
$14.7M Buy
473,051
+179,124
+61% +$5.57M 0.61% 55
2017
Q2
$9.3M Buy
293,927
+19,235
+7% +$609K 0.41% 91
2017
Q1
$6.22M Buy
274,692
+45,133
+20% +$1.02M 0.28% 118
2016
Q4
$5.01M Buy
229,559
+119
+0.1% +$2.6K 0.24% 132
2016
Q3
$6.05M Buy
229,440
+47,050
+26% +$1.24M 0.31% 117
2016
Q2
$3.6M Buy
+182,390
New +$3.6M 0.2% 138